Clinical Edge Journal Scan

Dactylitis Represents More Active and Severe PsA Phenotype


 

Key clinical point: The presence of clinical or subclinical dactylitis represented a more active and severe form of psoriatic arthritis (PsA), characterized by increased disease activity, swollen joint counts (SJCs), and tender joint counts (TJCs).

Major finding: PsA with dactylitis (clinical or subclinical) vs without dactylitis was associated with higher median disease activity index in PsA (DAPSA) scores (25.5 vs 16.1; P < .01), SJCs (4 vs 2; P < .001), and TJCs (4 vs 3; P < .01). PsA with subclinical dactylitis vs without dactylitis was associated with even higher DAPSA scores (27.2 vs 16.1; P < .05), SJCs (4.5 vs 2; P < .01), and TJCs (5 vs 3; P < .05).

Study details: This case-control study included 223 patients with PsA who were stratified on the basis of the presence of dactylitis (clinical or subclinical) or its absence at baseline.

Disclosures: This study was supported by the Youth Clinical Research Project of Peking University First Hospital and other sources. No conflicts of interest were reported.

Source: Song Z, Geng Y, Zhang X, Deng X, Zhang Z. Subclinical dactylitis represents a more active phenotype of psoriatic arthritis. Joint Bone Spine. Published online September 24, 2024. Source

Recommended Reading

FDA Approves Ustekinumab Biosimilar Otulfi
MDedge Rheumatology
Rapid Improvement in Disease Activity With Ixekizumab vs IL-23 and IL-12/23 Inhibitors in PsA
MDedge Rheumatology
Bimekizumab Rapidly Improves Patient-Reported Outcomes in PsA
MDedge Rheumatology
Weather Has a Limited Effect on PsA Symptoms
MDedge Rheumatology
Comparative Performance of Adalimumab and Secukinumab in PsA
MDedge Rheumatology
Secukinumab Promotes Long-Term Disease Control in PsA
MDedge Rheumatology
Guselkumab Shows Persistent Effects in PsA
MDedge Rheumatology
Intravenous Secukinumab Effective and Safe in PsA
MDedge Rheumatology
Impact of Smoking on Treatment Outcomes of Tofacitinib in PsA
MDedge Rheumatology
Guselkumab Demonstrates Sustained Efficacy and Safety in PsA
MDedge Rheumatology